Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Uso y Abuso de Los Anti-Inflamatorios en El Deporte
Uso y Abuso de Los Anti-Inflamatorios en El Deporte
en el deporte
Sesión académica
Club Atlas FC
EUCOSANOIDES
Ciclo-oxigenasa 1 y 2
PROSTAGLANDINAS
TIPO RECEPTOR FUNCIÓN
EP2 • Broncodilatador
• Relaja músculo liso intestinal
• Vasodilatación
Inespecíficos • Hiperalgesia
• Pirógeno
*J. A. Luis Chiesa, Ana C. B. Petersen: El ABC de las Prostaglandinas, Ediciones Toray, S.A. Barcelona,
1983
REPARACIÓN
Clasificación
Selectividad
Características farmacológicas
Potencia
*Dra Alicia Kassan Rank. Clínica del Dolor. Hospital general de México
Beneficios vs E. colaterales
A.I.N.ES (no selectivos)
Beneficios E. colaterales
Dolor Interferencia con el proceso de
cicatrización*
Inflamación Acelera el deterioro articular
en OA
Edema Retrasa la consolidación de
fracturas**
Incremento de la TA 5 mmHg
***
Exacerbación del asma
Daño renal
*Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis
of the knee. J Rheumatol 1995;22:1941-6.
**Simon AM, Manigrasso MB, O’Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res
2002;17:963-76.
***Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann
Intern Med 1994;121:289-300.
****
Ventajas COX2
*Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verbury KM, et al. Reduced incidence of gastroduodenal ulcers with
celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-
27.
*Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a
cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.
Gastroenterology 1999;117:776-83.
**US Food and Drug Administration. Celebrex capsules (celecoxib). NDA 20-998/S-009. 2000. Available:
www.fda.gov/ohrms/dockets/ac/01/briefing /3677b1_03_med.pdf (accessed 2002 Sept 12).
** US Food and Drug Administration. Vioxx gastrointestinal safety. NDA 21-042/S-007. 2000. Available:
www.fda.gov/ohrms/dockets/ac/01/briefing /3677b2_03_med.doc (accessed 2002 Sept 12).
Desventajas COX2
Trombosis *
Retención de sales y agua **
Cicatrización***
*Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA
2001;286:954-9.
*FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol
2001;19(Suppl 25):S31-6.
**Controversies in COX-2 selective inhibition. Simon LS. J Rheumatol. 2002 Jul;29(7):1501-10.
***Simon AM, Manigrasso MB, O’Connor JP. Cyclo-oxygenase 2 function is essentialfor bone fracture healing. J Bone
Miner Res 2002;17:963-76.
***Thorsson O, Rantanen J, Hurme T, et al. Effects of nonsteroidal antiinflammatory medication on satellite cell
proliferation during muscle regeneration. Am J Sport Med1998;26:172–6.
***Shen W, Li Y, Tang Y, et al. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by
decreasing regeneration and promoting fibrosis. Am J Pathol 2005;167:1105–17.
Anne-Marie Schjerning Olsen, et al. Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of
Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study. Circulation
published online May 9, 2011
Lesiones tendinosas
*Khan KM, Cook JL, Bonar F, et al. Histopathology of common tendinopathies: update and implications for clinical
management. Sports Med1999;27:393–408.
**Marsolais D, Coˆte´ CH, Frenetta J. NSAIDs reduce neutrophil and macrophage accumulation but does not improve
tendon regeneration. Lab Invest 2003;83:991–9.
***Magra M, Maffulli N. NSAIDs in tendinopathy: friend or foe. Clin J Sport Med 2006;16:1–3.
****Lane LB, Boretz RS, Stuchin SA. Treatment of De Quervain’s disease:role of conservative management. J Hand Surg
[Br] 2001;26:258–60.
****Petri M, Hufman SL, Waser G, et al. Celecoxib effectively treats patients with acute shoulder tendonitis/bursitis. J
Rheumatol 2004;31:1614–20.
Lesiones óseas
*Warner DC, Schnepf G, Barret MS, et al. Prevalence, attitudes, and behaviors related to the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) in student athletes. J Adolesc Health 2002;30:150–3.
Lesiones musculares
*Mackey AL, Kjaer M, Dandanell S, et al. The influence of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in humans. J Appl
Physiol 2007;103:425–31.
**Mehallo CJ, Drezner JA, Bytomski JR. Practical management: NSAIDs use in athletic injuries. Clin J Sport Med 2006;16:170–4.
Lesión miofibrilar
Muscle injuries and repair: The role of prostaglandins and inflammation. V. Prisk and J. Huard
Histol Histopathol (2003) 18: 1243-1256
J.-L. Ziltener et al. / Annals of Physical and Rehabilitation Medicine 53 (2010) 278–288
Non-steroidal anti-inflammatory drugs in sports medicine: guidelines for practical but sensible use. J A Paoloni. Br J Sports
Med 2009;43:863–865.
D.G.S.N.
Publicaciones